Literature DB >> 6692110

A Danish multicenter study: cefoxitin versus ampicillin + metronidazole in perforated appendicitis.

.   

Abstract

A prospective controlled randomized-block multicenter study was carried out in 209 patients undergoing surgery for perforated or ruptured appendicitis. The patients received either cefoxitin or ampicillin + metronidazole for 5 days. The treatment was started peroperatively. In both groups wound infections were found to be less than 10 per cent and no difference could be demonstrated. However cefoxitin was significantly superior to ampicillin + metronidazole in preventing intra-abdominal abscesses (P less than 0.05). Cefoxitin offers a single drug treatment that adequately reduces postoperative infectious complications in patients undergoing surgery for perforated or ruptured appendicitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692110     DOI: 10.1002/bjs.1800710223

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  4 in total

1.  Antibiotic prophylaxis in acute nonperforated appendicitis. The Danish Multicenter Study Group III.

Authors:  T Bauer; B Vennits; B Holm; J Hahn-Pedersen; D Lysen; H Galatius; E S Kristensen; P Graversen; F Wilhelmsen; H Skjoldborg
Journal:  Ann Surg       Date:  1989-03       Impact factor: 12.969

2.  Surgically treated gangrenous or perforated appendicitis. A comparison of aztreonam and clindamycin versus gentamicin and clindamycin.

Authors:  T V Berne; A E Yellin; M D Appleman; M A Gill; F C Chenella; P N Heseltine
Journal:  Ann Surg       Date:  1987-02       Impact factor: 12.969

3.  Adjunctive antimicrobial therapy for complicated appendicitis: bacterial overkill by combination therapy.

Authors:  J A Hopkins; S E Wilson; D G Bobey
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

4.  Cefotaxime lavage in children undergoing appendicectomy.

Authors:  T A McAllister; A H Fyfe; D G Young; P A Raine
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.